Amtrak is the U.S. intercity passenger rail provider and high-speed rail operator. The corporation operates commuter rail systems on behalf of several states and transit agencies.
The project is the cornerstone for Amtrak�� Gateway Program which targets rail service expansion through two proposed tunnels underneath the Hudson River. The tunnels will directly connect New Jersey and Penn Station in order to double capacity across the Hudson River.
However, trains passing through the new tunnels would cross an area on Manhattan�� west side kept aside for mixed-use development through a right-of-way. But without the tunnel box, construction of the new tunnels will be impossible.
According to the deal, Tutor Perini will construct an 800 feet long, 50 feet wide and 35 feet tall box tunnel which will extend from the 10th to the 11th Avenue and between 31st and 33rd Streets.
Best Mid Cap Companies To Invest In Right Now: Chanticleer Holdings Inc (HOTR)
Chanticleer Holdings, Inc., incorporated in 1999, is a business operator focused on expanding the Hooters casual dining restaurant brand in international markets. Chanticleer has rights to develop and operate Hooters restaurants in South Africa and has joint ventured with the current franchisee in Australia. The company also has franchise rights to develop Hungary and parts of Brazil while evaluating several additional opportunities internationally. During the year ended December 31, 2011, Chanticleer and a group of private equity investors acquired Hooters of America, Inc. (HOA). HOA is the franchisor and operator of over 450 Hooters restaurants in 44 states and 28 foreign countries. In October 2013, Chanticleer Holdings Inc purchased American Roadside Burgers, Inc. In December 12, 2013, Chanticleer Holdings Inc acquired a 51% interest in JF Restaurants LLC, an owner and operator of restaurants. In February 2014, it acquired Hooters' United States Pacific Northwest franchise rights and two existing restaurants in Oregon and Washington.
The Company operates in two business segments: Hooters franchise restaurants, and investment management and consulting services businesses. Hooters has also branched out to other areas, including licensing its name to a golf tour and the sale of packaged food in supermarkets. Its subsidiaries include Chanticleer Advisors, LLC, (Advisors), Avenel Ventures, LLC (Ventures), Avenel Financial Services, LLC (AFS), Chanticleer Holdings Limited (CHL), Chanticleer Holdings Australia Pty, Ltd. (CHA), Chanticleer Investment Partners, LLC (CIP), DineOut SA Ltd. (DineOut), Kiarabrite (Pty) Ltd (KPL), Dimaflo (Pty) Ltd (DFLO), Tundraspex (Pty) Ltd (TPL), Civisign (Pty) Ltd (CPL), Dimalogix (Pty) Ltd (DLOG) and Crown Restaurants Kft. (CRK).
South Africa
As of December 31, 2011, the Company had four Hooters locations in South Africa in Cape Town, Durban and Johannesburg (two locations), which are owned by four companies, which it control. The Com! pany formed a management company to operate the current South African Hooters locations. It owns 80% of the management company, with two members of local management owning the remaining 20%. The management company charges a management fee of 5% of net revenues to the Hooters locations in South Africa.
Other Countries
The Company has acquired development rights for Hooters in five states of Brazil, which would include Rio de Janeiro. It has applied to HOA for franchise rights in Hungary, where it own 80% of the entity the Company anticipate will hold the franchise rights and its local partner owns the remaining 20%. The Company has partnered with the Hooters franchisee in a joint venture in which it owns 49% and its partner 51%. The first Hooters restaurant under this joint venture (which would be the third Hooters restaurant open in Australia) opened in January 2012 in Campbelltown, a suburb of Sydney. It has a non-binding letter of intent with a franchisee to purchase 100% of an existing Hooters location.
Management and consulting services
The Company provides management and consulting services for small companies, which are seeking to become publicly traded. The Company also provides management and investment services for Investors LLC and Investors II, which are affiliates of the Company.
Advisors' Opinion:- [By Chris Isidore]
Restaurant chains are trying to hold the line on prices. Mark Allison, senior vice president of culinary operations at Chanticleer Holdings (HOTR), which operates the American Roadside Burger chain, said his chain raised prices about 12%, even though their beef costs are up even more than that.
Top Railroad Stocks For 2014: Vanguard Natural Resources LLC(VNR)
Vanguard Natural Resources, LLC, through its subsidiaries, engages in the acquisition and development of oil and natural gas properties in the United States. Its properties are located in the southern portion of the Appalachian Basin, primarily in southeast Kentucky and northeast Tennessee; the Permian Basin, primarily in west Texas and southeastern New Mexico; and south Texas. As of December 31, 2010, the company had estimated proved reserves of 69.3 million barrels of oil equivalent, as well as working interests in 2,270 net productive wells. Vanguard Natural Resources, LLC was founded in 2006 and is based in Houston, Texas.
Advisors' Opinion:- [By Tyler Crowe]
If you're looking for income investments, then it's awfully hard to argue with the massive distribution payments from LINN Energy (NASDAQ: LINE ) (NASDAQ: LNCO ) , Breitburn Energy Partners (NASDAQ: BBEP ) , and Vanguard Natural Resources (NASDAQ: VNR ) . Thing is, though, income investments need both a decent yield and a level of certainty that it will keep that distribution going for many years to come. Other than being high-yielding investments, they are also all master limited partnerships, which means you need to look beyond just the operations to see how these companies will stand the test of time.
- [By Matt DiLallo]
Oil and gas producer, Vanguard Natural Resources (NASDAQ: VNR ) is out with its first-quarter earnings. The company, known for its monthly distribution to investors, is one of a growing number of oil and gas production companies structured as an MLP/LLC. This makes the high yielder a favorite of income-starved investors. Let's take a quick look to ensure that income won't be drying up anytime soon.
- [By Matt DiLallo]
One company to watch here is�Vanguard Natural Resources (NASDAQ: VNR ) , which has eschewed increased organic production growth spending until now. However, the company is looking into the possibility of following LINN's blueprint and potentially change its game plan. Last year Vanguard was one of the most conservative E&P MLPs as its adjusted EBITDA was 4.6 times its capital spending. It's one company that certainly has the capacity to pursue organic production growth spending if it can change the philosophical mind-set that would be required to switch models.
Top Railroad Stocks For 2014: Central Europe Russia and Turkey Fund Inc (CEE)
Central Europe and Russia Fund, Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund seeks long-term capital appreciation primarily through investment in equity and equity-linked securities of issuers domiciled in Central Europe and Russia. The Fund's portfolio includes investments in Russian, Polish, Hungarian, Czech Republic, Turkish, Austrian, Dutch, Cyprus, Bermuda and Virgin Islands common stocks.
The Fund invests in various industries, including commercial banks, diversified telecommunication services, food products, metals and mining, personal products, wireless telecommunication services, building products, construction and engineering, diversified telecommunication services, media, pharmaceuticals, automobiles, and oil, gas and consumable fuels. The Fund is managed and advised by subsidiaries of the Deutsche Bank Group. The Fund's investment advisor is Deutsche Asset Management International GmbH. The Fund's manager is Deutsche Investment Management Americas Inc.
Advisors' Opinion:- [By Jake L'Ecuyer]
Among the financial stocks, Ashford Hospitality Trust (NYSE: AHT) was down more than 5.7 percent, while The Central Europe, Russia and Turkey Fund (NYSE: CEE) tumbled around 5 percent.
- [By STANSBERRYRESEARCH]
With emerging market speculation heating up again, TRF is trading for a 24% premium right now. If that premium climbs any higher, we predict another obliteration. – Brian Hunt, DailyWealth, December 21, 2006
We published that note in December 2006. By March 2009, it had lost more than 90% of its value. Perhaps more importantly to any long-term, buy-and-hold investor, the decline we foresaw in the fund would have wiped out more than 100% of the accumulated capital gains, assuming you invested as much as 15 years earlier. Now... I'd like you to look at the chart one more time. Look at what happened to the fund in the first half of 2009. It went nearly straight up. On April 17, 2009, we told subscribers to buy Russian stocks. Instead of using TRF, Steve Sjuggerud recommended a nearly identical Scudder Fund, the Central Europe and Russia Fund (NYSE: CEE). Both went up 150% from their March lows. So if you followed the buy-and-hold strategy in Russian stocks over the last 15 years, you would have made a very small amount of money – or lost money, depending on when you sold your shares. On the other hand, if you applied a few of our secrets, you could have easily traded this fund for more than 100% gains in only a few weeks. And if you watch this fund, you'll be able to make trades like this three or four times each decade. If you watch other similar funds, you'll be able to make trades like this once or twice a year. And let me tell you one more thing about this situation. In January 2007, when TRF was widely overvalued and when most individual investors were clamoring to buy shares – despite the premium valuation – we checked to see if we could sell the fund short. We knew it was going to collapse and wanted to profit directly as it fell. But we couldn't. Why not? Because other professionals had already borrowed all of the available shares to sh
Top Railroad Stocks For 2014: Varian Medical Systems Inc.(VAR)
Varian Medical Systems, Inc. designs, manufactures, sells, and services equipment and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery, and brachytherapy worldwide. Its Oncology Systems segment offers products, such as linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment, and accessories; and information management, treatment planning, and image processing software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, doctors? offices, and cancer care clinics. The company?s X-ray Products segment provides x-ray tubes for use in a range of applications, including computed tomography scanning, radiographic or fluoroscopic imaging, mammography, special procedures, and industrial applications; and flat panel digital image detectors for filmless x-ray imaging. It sells t hese products to imaging systems original equipment manufacturers that incorporate them into their medical diagnostic, dental, veterinary, and industrial imaging systems; independent service companies; and directly to end-users. The company also designs, manufactures, sells, and services Linatron x-ray accelerators, imaging processing software, and image detection products for security and inspection purposes, such as cargo screening at ports and borders, and nondestructive examination in various applications. In addition, it develops products and systems for delivering proton therapy; and technologies in the areas of digital X-ray imaging technology, volumetric and functional imaging, improved X-ray sources, and technology for security and cargo screening applications. The company was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. Varian Medical Systems, Inc. was founded in 1948 and is headquartered in Palo Alto , California.
Advisors' Opinion:- [By Holly LaFon]
Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-颅��hirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe ��a 60% market share. As impressive as that may sound, the availability of state-颅��f-颅��he-颅��rt radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-颅��erm growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-颅��anel services business, plus their X-颅��ay tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their prot
- [By WWW.GURUFOCUS.COM]
Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-颅��hirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe ��a 60% market share. As impressive as that may sound, the availability of state-颅��f-颅��he-颅��rt radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-颅��erm growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-颅��anel services business, plus their X-颅��ay tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their pro
No comments:
Post a Comment